autarkize | $2,502,492 | (Nov 1, 2024)
Keel | $5,933,454 | (Nov 1, 2024)
Decart | $21,000,000 | (Nov 1, 2024)
Oova
United States
- New York, NY
- 14/06/2023
- Series A
- $10,300,000
Oova is the fertility translator that fully illuminates a woman's fertility, giving her and her care team the clearest steps to conception.
Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to both patients and healthcare providers. Oova's at-home urine test measures both luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience.
- Industry Biotechnology
- Website https://oova.life/
- LinkedIn https://www.linkedin.com/company/oova-inc/
Related People
Aparna (Amy) Divaraniya, PhDFounder
United States -
New York, New York
Experienced leader with a demonstrated history of working in the biotechnology industry. Skilled in Biomarkers, Electronic Lab Notebooks, Oncology, Team Building, and Biotechnology. Strong business development professional with a Doctor of Philosophy (PhD) focused in Genetics and Genomics Sciences from Icahn School of Medicine at Mount Sinai.
I have a strong passion to change women's healthcare. It's outstanding to me that there has only been incremental advancement in this space in the past few decades. My ultimate goal with OOVA is to empower women to take control of their health by being armed with accurate information about their body.
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MOTORMIA | $8,000,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Ataraxis AI | $4,000,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)
LINGO | $2,250,000 | (Nov 1, 2024)
ContraForce | $3,250,000 | (Nov 1, 2024)